
Currently out of the existing stock ratings of Jack Meehan, 54 are a BUY (48.65%), 40 are a HOLD (36.04%), 17 are a SELL (15.32%).
Analyst Jack Meehan, currently employed at BARCLAYS, has had 92.73% of price targets met with an average potential upside of 28.15%, reached in 287 days on average.
Jack Meehan has documented 233 price targets and ratings displayed on 23 stocks. The coverage is on Consumer Cyclical, Healthcare sectors.
Most recent stock forecast was given on QGEN, Qiagen NV at 05-Oct-2026.
Analyst best performing recommendations are on INMD.
The best stock recommendation documented was for INMD on 11/6/2019. The price target of $22.5 was fulfilled within 5 days with a profit of $3.07 (15.8%), with a performance score of 31.6.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 19-Sep-2025
$90
10 months 5 days ago
(12-Jan-2026)
1/5 (20%)
$23.67 (35.69%)
343
Buy Since 05-Jan-2026
$78
$1.99 (2.62%)
$78
10 months 12 days ago
(05-Jan-2026)
22/25 (88%)
$3.25 (4.35%)
178
Hold Since 28-Jul-2022
$76
$69
1 years 6 days ago
(11-Nov-2025)
8/13 (61.54%)
$1.4 (1.88%)
72
Buy Since 12-Oct-2022
$78
$70
1 years 25 days ago
(23-Oct-2025)
5/14 (35.71%)
$4.11 (5.56%)
90
Buy Since 27-Jun-2024
$76
$78
1 years 26 days ago
(22-Oct-2025)
2/4 (50%)
$2.07 (2.80%)
163
Which stock is Jack Meehan most bullish on?
Which stock is Jack Meehan most reserved on?
What Year was the first public recommendation made by Jack Meehan?